Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05206448
Other study ID # 201906826
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date October 26, 2020
Est. completion date December 2024

Study information

Verified date December 2023
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the addition of clomiphene citrate (CC) to letrozole for the treatment of infertility in women with polycystic ovary syndrome across a course of two treatment cycles with stair step dosing of letrozole similar to standard of care. Half of the participants will receive letrozole and CC in combination, while the other half will receive letrozole alone.


Description:

Letrozole and Clomid are both used for ovulation induction, but they have different mechanisms of action. In a pilot study we found that the combination of letrozole 2.5 mg and CC 50 mg nearly doubled the ovulation rate as compared to use of letrozole monotherapy (77% vs. 43%, P=0.007; rate ratio for ovulation (95% CI) 1.80 (1.18 to 2.75), with similar endometrial thickness and number of follicles across treatment arms among those who ovulated. Additional data is needed to evaluate escalating dosages, multiple cycles, live birth and multiple gestation with this novel treatment combination. This is a randomized controlled trial of letrozole versus letrozole and clomiphene citrate (CC) for up to three menstrual cycles. Women will be randomized in a 1:1 ratio to receive letrozole 2.5 mg or combination of letrozole 2.5 mg and clomiphene 50 mg for 5 days on days 3-7 of menstrual cycle. The women and their partners will be instructed to have regular intercourse with the intent to conceive during the cycle. Patients will have an transvaginal ultrasound in the mid-luteal phase of cycle to assess corpora lutea number and endometrial thickness. Patients will have mid- luteal phase progesterone level drawn to evaluate ovulation. Patients in both study arms who do not ovulate will have their Letrozole dose increased by 2.5 mg in the next study cycle to a max of 7.5 mg. Patients in the combination arm who do not ovulate will only have their Letrozole dose increased and will continue to receive the same dose of clomiphene across the three study treatment cycles. Side effect profile will also be monitored.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 189
Est. completion date December 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Willing to comply with all study procedures and be available for the duration of the study 2. Diagnosis of infertility: Inability of couple to achieve successful pregnancy after 12 months of regular time unprotected intercourse in women less than 35 years of age; and after 6 months of regular intercourse without use of contraception in women 35 years and older. Women that have anovulation or oligomenorrhea are also considered to meet diagnosis of infertility, without meeting the time constraints described above. 3. Diagnosis of polycystic ovary syndrome based on Revised Rotterdam criteria. 4. Ability to have regular intercourse during the ovulation induction phase of the study. 5. Partner with a normal sperm concentration of 15 million/mL and with normal motility of >40% according to World Health Organization cutoff points or greater than 10 million total motile sperm count OR has fathered a pregnancy in the past. Exclusion Criteria: 1. Current pregnancy 2. Current use of hormonal contraception; use of any type of combined contraceptive or oral progestins within the past month; or use of hormonal implants or depo progestins within the past 3 months 3. Other known cause of infertility: endometriosis, tubal factor, uterine abnormalities 4. Uncorrected thyroid disease 5. Untreated hyperprolactinemia 6. Medical conditions in which avoiding pregnancy is recommended until under improved control: poorly controlled Type 1 or Type 2 diabetes, poorly controlled hypertension 7. Contraindications to clomiphene citrate: hypersensitivity to clomiphene citrate or any of its components, history of liver disease or known liver disease, unknown cause of abnormal uterine bleeding, or intracranial lesion 8. Contraindications to letrozole: hypersensitivity to letrozole or any of its components 9. Use of medications known to affect reproductive function or metabolism or that are an absolute contraindication during pregnancy within the past month 10. If patients are suspected based on clinical findings for other etiologies that mimic PCOS, work up must be completed to exclude other etiologies prior to enrollment (i.e. Cushing's syndrome, androgen-secreting tumor)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Letrozole
Letrozole tablet
Clomiphene Citrate
Clomiphene Citrate tablet

Locations

Country Name City State
United States University of Iowa Hospitals & Clinics - Davenport Clinic Davenport Iowa
United States University of Iowa Hospitals & Clinics Iowa City Iowa
United States University of Wisconsin Madison Wisconsin
United States University of Iowa Hospitals & Clinics- West Des Moines Clinic West Des Moines Iowa

Sponsors (4)

Lead Sponsor Collaborator
Rachel Mejia American Society for Reproductive Medicine, Society for Reproductive Investigation, University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ovulation Mid-luteal serum progesterone level >=3 ng/ml Tested 6 to 8 days following patient reporting a positive ovulation test (LH surge). If no surge is detected, progesterone lab will be drawn on Cycle day 21-24.
Secondary Number of corpora lutea Number of corpora lutea on ultrasound Cycle day 21-24 of 1st treatment cycle
Secondary Number of corpora lutea Number of corpora lutea on ultrasound Cycle day 21-24 of 2nd treatment cycle
Secondary Number of corpora lutea Number of corpora lutea on ultrasound Cycle day 21-24 of 3rd treatment cycle
Secondary Endometrial thickness Endometrial thickness assessed by ultrasound Cycle day 21-24 of 1st treatment cycle
Secondary Endometrial thickness Endometrial thickness assessed by ultrasound Cycle day 21-24 of 2nd treatment cycle
Secondary Endometrial thickness Endometrial thickness assessed by ultrasound Cycle day 21-24 of 3rd treatment cycle
Secondary Conception positive serum or urinary test of hCG 5 weeks after treatment in treatment cycles 1, 2, and 3 (treatment cycle is 24-35 days depending on ovulation)
Secondary Clinical pregnancy intrauterine pregnancy with fetal heart motion determined by ultrasound 6 to 7 weeks after treatment in treatment cycles 1, 2, and 3 (treatment cycle is 24-35 days depending on ovulation)
Secondary Multiple gestation intrauterine pregnancy with more than one fetal heart motion determined by ultrasound 6 to 7 weeks after treatment in treatment cycles 1, 2, and 3 (treatment cycle is 24-35 days depending on ovulation)
Secondary Live birth delivery of a live born infant determined by medical record abstraction 9-10 months following final treatment cycle (treatment cycle is 24-35 days depending on ovulation)
Secondary Multiple birth delivery of more than one infant determined by medical record abstraction 9-10 months following final treatment cycle (treatment cycle is 24-35 days depending on ovulation)
Secondary Pregnancy Loss biochemical pregnancy, miscarriage, or ectopic pregnancy determined by ultrasound or medical record abstraction Through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A